Soochow Securities medical team issued a strongly bullish note on Dongcheng Pharmaceutical (002675.SZ), arguing its subsidiary Lanacheng's radiopharmaceutical pipeline is significantly undervalued. The note details 13 pipeline assets, including 7 diagnostic and 6 therapeutic radiopharmaceuticals, with several in late-stage clinical trials or NDA submission.
Broker sees Dongcheng Pharmaceutical's radiopharmaceutical unit as deeply undervalued and recommends buying the stock.
Free preview — more China A-share & HK research · About Us · Legal & Privacy